VERTEX PHARMACEUTICALS INC / MA (VRTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 5B 10B 15B Q3 '16: 1.7B Q4 '16: 1.7B Q1 '17: 2B Q2 '17: 2.1B Q3 '17: 2.3B Q4 '17: 2.5B Q1 '18: 2.4B Q2 '18: 2.6B Q3 '18: 2.8B Q4 '18: 3B Q1 '19: 3.3B Q2 '19: 3.5B Q3 '19: 3.6B Q4 '19: 4.2B Q1 '20: 4.8B Q2 '20: 5.4B Q3 '20: 6B Q4 '20: 6.2B Q1 '21: 6.4B Q2 '21: 6.7B Q3 '21: 7.1B Q4 '21: 7.6B Q1 '22: 7.9B Q2 '22: 8.4B Q3 '22: 8.7B Q4 '22: 8.9B Q1 '23: 9.2B Q2 '23: 9.5B Q3 '23: 9.7B Q4 '23: 9.9B Q1 '24: 10.2B Q2 '24: 10.3B Q3 '24: 10.6B Q4 '24: 11B Q1 '25: 11.1B Q2 '25: 11.4B Q3 '25: 11.7B Q4 '25: 12B Q1 '26: 12.2B Q2 '26: 12.6B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-2B 0 2B 4B 6B Q3 '16: -83.4M Q4 '16: 9.9M Q1 '17: 295.1M Q2 '17: 344.5M Q3 '17: 37.1M Q4 '17: 123.2M Q1 '18: -18.7M Q2 '18: 101.5M Q3 '18: 633.2M Q4 '18: 635.1M Q1 '19: 783.1M Q2 '19: 880.1M Q3 '19: 773.8M Q4 '19: 1.2B Q1 '20: 1.6B Q2 '20: 2.1B Q3 '20: 2.7B Q4 '20: 2.9B Q1 '21: 3B Q2 '21: 2.3B Q3 '21: 2.7B Q4 '21: 2.8B Q1 '22: 2.9B Q2 '22: 4.1B Q3 '22: 4.2B Q4 '22: 4.3B Q1 '23: 4B Q2 '23: 4B Q3 '23: 3.9B Q4 '23: 3.8B Q1 '24: 4.2B Q2 '24: -348.6M Q3 '24: -270.4M Q4 '24: -232.9M Q1 '25: -742.3M Q2 '25: 3.9B Q3 '25: 4B Q4 '25: 4.2B Q1 '26: 4.7B Q2 '26: 4.8B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-1.5B 0 1.5B 3B 4.5B Q3 '16: -218.7M Q4 '16: -112.1M Q1 '17: 177.3M Q2 '17: 259.9M Q3 '17: 195.7M Q4 '17: 263.5M Q1 '18: 226M Q2 '18: 415.4M Q3 '18: 647.1M Q4 '18: 2.1B Q1 '19: 2.2B Q2 '19: 2.2B Q3 '19: 2.1B Q4 '19: 1.2B Q1 '20: 1.5B Q2 '20: 2.1B Q3 '20: 2.7B Q4 '20: 2.7B Q1 '21: 2.8B Q2 '21: 2B Q3 '21: 2.2B Q4 '21: 2.3B Q1 '22: 2.5B Q2 '22: 3.2B Q3 '22: 3.3B Q4 '22: 3.3B Q1 '23: 3.3B Q2 '23: 3.4B Q3 '23: 3.5B Q4 '23: 3.6B Q1 '24: 4B Q2 '24: -489.9M Q3 '24: -479.8M Q4 '24: -535.6M Q1 '25: -988.9M Q2 '25: 3.6B Q3 '25: 3.7B Q4 '25: 4B Q1 '26: 4.3B Q2 '26: 4.4B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 600M 1.2B 1.8B Q4 '17: 275.1M Q1 '18: 299.7M Q2 '18: 332.9M Q3 '18: 371.3M Q4 '18: 409.5M Q1 '19: 433M Q2 '19: 464.4M Q3 '19: 485M Q4 '19: 547.8M Q1 '20: 615.2M Q2 '20: 663.9M Q3 '20: 718.2M Q4 '20: 736.3M Q1 '21: 766.1M Q2 '21: 809.6M Q3 '21: 859.9M Q4 '21: 904.2M Q1 '22: 957.7M Q2 '22: 991.5M Q3 '22: 1B Q4 '22: 1.1B Q1 '23: 1.1B Q2 '23: 1.1B Q3 '23: 1.2B Q4 '23: 1.3B Q1 '24: 1.3B Q2 '24: 1.4B Q3 '24: 1.5B Q4 '24: 1.5B Q1 '25: 1.6B Q2 '25: 1.6B Q3 '25: 1.6B Q4 '25: 1.7B Q1 '26: 1.7B Q2 '26: 1.8B Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-1.5B 0 1.5B 3B 4.5B Q3 '16: 120.5M Q4 '16: 236.1M Q1 '17: 516.9M Q2 '17: 657.7M Q3 '17: 762.2M Q4 '17: 844.9M Q1 '18: 831.9M Q2 '18: 972M Q3 '18: 1.2B Q4 '18: 1.3B Q1 '19: 1.3B Q2 '19: 1.5B Q3 '19: 1.4B Q4 '19: 1.6B Q1 '20: 2.1B Q2 '20: 2.6B Q3 '20: 3.2B Q4 '20: 3.3B Q1 '21: 3.4B Q2 '21: 2.1B Q3 '21: 2.1B Q4 '21: 2.6B Q1 '22: 2.7B Q2 '22: 4B Q3 '22: 4B Q4 '22: 4.1B Q1 '23: 4.1B Q2 '23: 4.1B Q3 '23: 4.4B Q4 '23: 3.5B Q1 '24: 3.9B Q2 '24: -944M Q3 '24: -842.6M Q4 '24: -492.6M Q1 '25: -980.3M Q2 '25: 3.8B Q3 '25: 3.7B Q4 '25: 3.6B Q1 '26: 4.2B Q2 '26: 4.3B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-1.5B 0 1.5B 3B 4.5B Q3 '16: 66.2M Q4 '16: 179.5M Q1 '17: 461.2M Q2 '17: 600.6M Q3 '17: 690.9M Q4 '17: 745.5M Q1 '18: 714.3M Q2 '18: 842.1M Q3 '18: 1.1B Q4 '18: 1.2B Q1 '19: 1.3B Q2 '19: 1.4B Q3 '19: 1.4B Q4 '19: 1.5B Q1 '20: 2B Q2 '20: 2.6B Q3 '20: 3B Q4 '20: 3B Q1 '21: 3B Q2 '21: 1.8B Q3 '21: 1.9B Q4 '21: 2.4B Q1 '22: 2.5B Q2 '22: 3.8B Q3 '22: 3.8B Q4 '22: 3.9B Q1 '23: 3.9B Q2 '23: 3.9B Q3 '23: 4.2B Q4 '23: 3.3B Q1 '24: 3.7B Q2 '24: -1.2B Q3 '24: -1.1B Q4 '24: -790.3M Q1 '25: -1.3B Q2 '25: 3.5B Q3 '25: 3.3B Q4 '25: 3.2B Q1 '26: 3.7B Q2 '26: 3.8B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 90M 180M 270M Q1 '15: 239.5M Q2 '15: 240.8M Q3 '15: 242M Q1 '16: 243.8M Q2 '16: 244.5M Q3 '16: 244.9M Q4 '16: 247.8M Q1 '17: 248.7M Q2 '17: 251.6M Q3 '17: 250.3M Q4 '17: 256.8M Q1 '18: 258.5M Q2 '18: 258.6M Q3 '18: 259.8M Q4 '18: 259.8M Q1 '19: 260.2M Q2 '19: 259.8M Q3 '19: 260.5M Q4 '19: 262.1M Q1 '20: 263.5M Q2 '20: 263.4M Q3 '20: 264.1M Q4 '20: 263.1M Q1 '21: 261.9M Q2 '21: 261M Q3 '21: 259.7M Q1 '22: 257.9M Q2 '22: 258.7M Q3 '22: 259.5M Q1 '23: 260.3M Q2 '23: 260.4M Q3 '23: 260.6M Q1 '24: 261.1M Q2 '24: 258.1M Q3 '24: 261M Q1 '25: 259.5M Q2 '25: 258.9M Q3 '25: 257.6M Q1 '26: 256.3M Q2 '26: 255.2M Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 0.00 6.00 12.00 18.00 Q3 '16: -0.90 Q4 '16: -0.46 Q1 '17: 0.70 Q2 '17: 1.03 Q3 '17: 0.78 Q4 '17: 1.04 Q1 '18: 0.86 Q2 '18: 1.59 Q3 '18: 2.50 Q4 '18: 8.08 Q1 '19: 8.30 Q2 '19: 8.53 Q3 '19: 8.25 Q4 '19: 4.51 Q1 '20: 5.77 Q2 '20: 7.92 Q3 '20: 10.23 Q4 '20: 10.30 Q1 '21: 10.50 Q2 '21: 7.58 Q3 '21: 8.33 Q4 '21: 9.01 Q1 '22: 9.48 Q2 '22: 12.35 Q3 '22: 12.66 Q4 '22: 12.82 Q1 '23: 12.55 Q2 '23: 12.94 Q3 '23: 13.32 Q4 '23: 13.89 Q1 '24: 15.41 Q2 '24: -2.03 Q3 '24: -1.99 Q4 '24: -2.08 Q1 '25: -3.80 Q2 '25: 14.11 Q3 '25: 14.30 Q4 '25: 15.32 Q1 '26: 16.85 Q2 '26: 17.17 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.